{"abstract": "Valeant Pharmaceuticals has raised its takeover bid for Allergan. | An offer by Pilgrim\u2019s Pride sets up a potential battle over Hillshire Brands. | Pimco has brought back a former top executive. | Fabrice Tourre said that he would not appeal his case in higher court.", "web_url": "https://dealbook.nytimes.com/2014/05/28/morning-agenda-valeant-turns-up-the-heat/", "snippet": "Valeant Pharmaceuticals has raised its takeover bid for Allergan. | An offer by Pilgrim\u2019s Pride sets up a potential battle over Hillshire Brands. | Pimco has brought back a former top executive. | Fabrice Tourre said that he would not appeal his c...", "lead_paragraph": "VALEANT RAISES BID FOR ALLERGAN \u00a0|\u00a0 Valeant Pharmaceuticals on Wednesday raised its takeover bid for Allergan, turning up the heat in its pursuit of the Botox maker, Michael J. de la Merced writes in DealBook. The new offer comes on the heels of a separate deal in which Nestl\u00e9 will buy the sales rights to some of Valeant\u2019s skin care products for $1.4 billion. It also arrives a day after Allergan unveiled a more pointed defense against the takeover bid, questioning the sustainability of its unwanted suitor\u2019s business model and stock price. ", "source": "The New York Times", "multimedia": [], "headline": {"main": "Valeant Turns Up the Heat", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [], "pub_date": "2014-05-28T12:06:51+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Sydney Ember", "person": [{"firstname": "Sydney", "middlename": null, "lastname": "Ember", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/d3896317-bde0-5e48-a07b-747a5f59070a", "word_count": 1874, "uri": "nyt://article/d3896317-bde0-5e48-a07b-747a5f59070a"}